Anna Radomińska‐Pandya
Researcher
Also affiliated: Tufts University (2008); Arkansas Children's Hospital (2011–2012); Salk Institute for Biological Studies (2001–2003); University of Helsinki (2006–2014); Howard Hughes Medical Institute (2001–2003); Eastern Virginia Medical School (2006); Gdańsk University of Technology (2012); École Nationale Vétérinaire de Toulouse (1999); Washington University in St. Louis (2009); University of Michigan (2012); University of Arkansas Medical Center (2000–2021); Helsinki Institute of Physics (2008); University of Alabama at Birmingham (2000); Cayman Chemical (United States) (2012); Arkansas Cardiology (2012); Korea Pharma (South Korea) (2008); BioChem Technology (United States) (2007); Centre de Recherche en Automatique de Nancy (1999); Arkansas State Crime Laboratory (2011–2012); Arkansas Department of Health (2009–2012); Gdańsk Medical University (2012); Université de Lorraine (1999)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Anna Radomińska‐Pandya's research examines the role of cannabinoid receptors as potential targets for anti-cancer drug development, with a recent focus on Ewing sarcoma. Her work has investigated both natural and synthetic cannabinoids, exploring their impact on Ewing sarcoma cell viability, potentially through non-canonical CB receptors. Radomińska‐Pandya holds a high-impact researcher designation, evidenced by an h-index of 40 and over 6,000 citations across her 117 publications. She collaborates with several colleagues at the University of Arkansas for Medical Sciences, including Alicja Urbaniak, Paul L. Prather, Amal Shoeib, and Azure L. Yarbrough, with whom she has co-authored multiple publications.
Metrics
- h-index: 40
- Publications: 117
- Citations: 6,038
Selected Publications
-
Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development (2021)
-
Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors (2021)
-
Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics (2020)
-
Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity (2020)
-
Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid <i>N</i>‐(adamantan‐1‐yl)‐1‐(5‐fluoropentyl)‐1<i>H</i>‐indole‐3‐carboxamide (STS‐135) (2020)
-
Oxidative Metabolism and Comparative Analysis of Synthetic Cannabinoid N‐(1‐adamantyl)‐1‐(5‐fluoropentyl)indazole‐3‐carboxamide (5F‐AKB‐48) and the Unfluorinated Analog AKB‐48 (2019)
-
Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22) (2019)
-
Oxidative metabolism of synthetic cannabinoid STS-135 by recombinant P450S and human liver microsomes (2019)
-
Natural compounds activating cannabinoid receptors CB1 and CB2: future for cancer treatments (2018)Acta Biochimica Polonica OpenAlex
-
Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice (2018)
-
Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ9-THC (2018)
-
Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants (2018)
-
Biological Activity of Resveratrol‐Hydroxycinnamic Acid Ester Conjugates (2017)
-
Identification of Novel Variants of the CB <sub>1</sub> Cannabinoid Receptor in Cancer Cells (2017)
-
Synthetic Cannabinoids: Rapidly Emerging Drugs of Abuse (2017)
Collaboration Network
Top Collaborators
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
Similar Researchers
Based on overlapping research topics